Why Iressa failed: toward novel use of kinase inhibitors (outlook)

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal Growth Factor Receptor (EGFR) inhibitors like Iressa show limited efficacy as monotherapy in cancers with downstream oncogenic alterations.
• Monotherapy with EGFR inhibitors can be ineffective due to cancer cells' mitogen-independent proliferation.
• Combining EGFR inhibitors with chemotherapy may cause antagonism or increased side effects.

Purpose of the Study:

• To review the reasons behind the clinical failure of Iressa as a monotherapy.
• To explore novel therapeutic strategies utilizing signal transduction inhibitors.
• To identify patient populations who may benefit from combination therapies.

Main Methods:

• Review of existing clinical trial data and scientific literature on EGFR inhibitors.
• Analysis of mechanisms underlying cancer cell proliferation and drug resistance.
• Discussion of potential synergistic interactions between signal transduction inhibitors and chemotherapy.

Main Results:

• EGFR levels and Iressa dosage do not consistently correlate with clinical response.
• Cancer's downstream oncogenic changes limit the effectiveness of EGFR inhibitors alone.
• Potential for antagonism or increased toxicity when combining EGFR inhibitors with chemotherapy.

Conclusions:

• A novel strategy involves using signal transduction inhibitors to enhance chemotherapy's therapeutic index.
• Combining Iressa with cycle-dependent and apoptosis-inducing chemotherapies offers a promising approach.
• This strategy could benefit patients unresponsive to kinase inhibitor monotherapy, supported by molecular diagnostics.